Filament Health Corp (OP:FLHLF)

0.0001 UNCHANGED

Last Price Updated: 10:57 AM EDT, Apr 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Filament Health Corp

< Previous 1 2 3 Next >

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression

March 16, 2026

Via ACCESS Newswire

Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS

July 08, 2025

Via ACCESS Newswire

Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia

May 29, 2024

Via ACCESSWIRE

Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More ↗

April 17, 2024

Via Benzinga

Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More ↗

March 30, 2024

Via Benzinga

Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More ↗

March 01, 2024

Via Benzinga

Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More ↗

February 15, 2024

Via Benzinga

'Rainforests Are Nature's Medicine Cabinets': Biotech Co. Performs Fresh Research On Traditional Plants For Modern Mental Health Challenges ↗

January 30, 2024

Via Benzinga

Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More ↗

January 26, 2024

Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available.

Via Benzinga

Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More ↗

December 27, 2023

President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also...

Via Benzinga

Magdalena Biosciences Initiates Preclinical Study to Evaluate Plant Extracts to Treat Depression, Anxiety, ADHD and Other Mental Health Indications

October 23, 2023

Via ACCESSWIRE

Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More ↗

September 26, 2023

Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge

Via Benzinga

Topics Economy

Peru's Coca Leaf Will Be Used For Research Toward Treating ADHD, Learn The Details ↗

September 21, 2023

Magdalena Biosciences, Jaguar Health (NASDAQ: JAGX) and Filament Health (OTCQB: FLHLF)

Via Benzinga

Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating ADHD

September 21, 2023

Via ACCESSWIRE

Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials ↗

August 23, 2023

Starting this October, scientists at Imperial College London’s (ICL) Centre for Psychedelic Research will assess psilocybin-assisted therapy for gambling addiction, noted Psychedelic Spotlight.

Via Benzinga

Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports ↗

August 21, 2023

Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds

Via Benzinga

Topics Cannabis Economy

Filament Health Shares Q1 2023 Financials, Material Uncertainties Upon Securing Additional Financing ↗

August 15, 2023

Natural psychedelic drug development company Filament Health (OTCQB: FLHLF) has released its unaudited consolidated, condensed financial results for Q1 2023 ended June 30. Numbers show:

Via Benzinga

The Power Play by The Market Herald Releases New Interviews with Etruscus Resources, Filament Health and Lancaster Resources Discussing Their Latest News

July 25, 2023

Via ACCESSWIRE

Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More ↗

July 24, 2023

Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal...

Via Benzinga

Filament Health Uplisting To NASDAQ In A $210M SPAC Deal ↗

July 19, 2023

Canadian clinical-stage natural psychedelics company Filament Health (OTCQB: FLHLF) has entered into a definitive agreement with Jupiter Acquisition Corp. (NASDAQ: JAQC), a Special Purpose Acquisition...

Via Benzinga

Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More ↗

July 11, 2023

First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic...

Via Benzinga

Filament Supplies Botanical Psilocybin To Canadian Researchers, Inks Global Licensing Deal ↗

July 07, 2023

Clinical-stage natural psychedelics company Filament Health (OTCQB: FLHLF) will supply psilocybin for two clinical studies funded by the Canadian Institutes of Health Research (CIHR) operating grants...

Via Benzinga

UCSF Clinical Trial Shows Promising Results For Naturally-Sourced Psilocybin And Psilocin ↗

May 30, 2023

A Phase 1 clinical trial led by the University of California San Francisco (UCSF) assessing research partner Filament Health Corp.’s (OTCQB: FLHLF) botanical psychedelic drug candidates has shown...

Via Benzinga

Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More ↗

May 23, 2023

Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application...

Via Benzinga

African Iboga Root Heads To Canadian Company Developing Natural Drugs To Help Treat Addictions ↗

May 17, 2023

Clinical-stage natural psychedelics company Filament Health Corp. (OTCQB: FLHLF) has completed the first-ever Nagoya Protocol-compliant import of Tabernanthe iboga root from Gabon to the company’s R&D...

Via Benzinga

Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More ↗

May 15, 2023

Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths...

Via Benzinga

Filament Health's Q1 2023 Financial Results, Material Uncertainty On The Horizon ↗

May 15, 2023

Natural psychedelics drug developer Filament Health Corp. (OTCQB: FLHLF) shared its interim financial results and further business highlights for the first quarter ended March 31, 2023.

Via Benzinga

Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More ↗

April 17, 2023

Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules

Via Benzinga

Two Psychedelics Companies Collaborate To Provide Clinical-Grade MDMA Capsules For Authorized Patients And Studies ↗

April 11, 2023

MDXX-class molecules producer PharmAla Biotech Holdings Inc.

Via Benzinga

Filament Health: 2022 Financials And Operational Highlights From Creator Of The Ayahuasca Pill ↗

April 03, 2023

The natural psychedelics company responsible for creating the first standardized ayahuasca capsule, Filament Health Corp.

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.